Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02060903 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
A Phase 3 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 379
- Enrollment target
NCT02060903: Completed Phase 3 study, sponsored by Dr. Reddy's Laboratories Limited.
NCT02060903 is a Phase 3 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 379 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02060903, a Phase 3 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 379 participants
- Enrollment target
Study Summary
The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home.
Primary Outcome
Proportion of index subjects randomized into the study who are lice free at all follow up visits through to the Day 14 visit. The index subject of a household was the youngest person within that household with at least 3 live lice present, as assessed over a period of up to 15 minutes at the Screening Visit.
Interventions
- DRUG Vehicle Lotion
- DRUG Abametapir Lotion 0.74% w/w
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 379 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
What the finished NCT02060903 record still lists
NCT02060903 is an interventional study that assigns participants to a tested intervention. The registered 379 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Lotion is the first listed.
NCT02060903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02060903 about?
NCT02060903 is a clinical study titled "A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation". The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home.
What is the current status of trial NCT02060903?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 379 participants. The study started on 2014-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02060903?
The interventions under investigation include: Vehicle Lotion (DRUG), Abametapir Lotion 0.74% w/w (DRUG).
Who is sponsoring clinical trial NCT02060903?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02060903's enrollment target sits among peer trials
379 987th of 2000 higher than 1,013 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia